XML 51 R11.htm IDEA: XBRL DOCUMENT v3.25.1
Leases
3 Months Ended
Mar. 31, 2025
Leases [Abstract]  
Leases Leases
Our operating leases that have commenced have terms that expire beginning 2025 through 2036 and consist of office space and research and development laboratories, including our corporate headquarters. Certain of these lease agreements contain clauses for renewal at our option. As we were not reasonably certain to exercise any of these renewal options at commencement of the associated leases, no such options were recognized as part of our right-of-use (ROU) assets or operating lease liabilities.
The following table presents supplemental operating lease information for operating leases that have commenced.
Three Months Ended
March 31,
(in millions, except weighted average data)20252024
Operating lease cost$16.5 $9.4 
Sublease income(0.9)(0.4)
Net operating lease cost$15.6 $9.0 
Cash paid for amounts included in the measurement of operating lease liabilities$9.3 $6.1 
March 31,
20252024
Weighted average remaining lease term
10.6 years10.6 years
Weighted average discount rate4.9 %5.1 %
Restricted cash related to letters of credit issued in lieu of cash security deposits$7.8 $7.8 
The following table presents approximate future non-cancelable minimum lease payments under operating leases and sublease income as of March 31, 2025.
(in millions)
Operating
Leases (1)
Sublease
Income
2025 (9 months remaining)
$32.5 $(2.6)
2026
58.3 (3.5)
2027
59.2 (3.5)
2028
60.7 (3.5)
2029
60.8 (3.5)
Thereafter374.4 (5.4)
Total operating lease payments (sublease income)645.9 $(22.0)
Less imputed interest
152.8 
Total operating lease liabilities493.1 
Less current operating lease liabilities included in other current liabilities45.6 
Noncurrent operating lease liabilities$447.5 
_________________________
(1) Amounts presented in the table above exclude $0.9 million for 2025, $1.7 million for 2026, and $0.9 million for 2027 of approximate non-cancelable future minimum lease payments under operating leases that have not yet commenced.